CareLit · DOI-Nachweis · Diabetologie und Stoffwechsel
A single-dose pharmacokinetic study of basal insulin peglispro (BIL) in subjects with hepatic impairment
DOI 10.1055/s-0035-1549750
Bibliografische Angaben
Nachweis in CareLit
Autor:innenSL Choi, C Loghin, P Garhyan, MP Knadler, E Lam, V Sinha, N Porksen, H Linnebjerg
ZeitschriftDiabetologie und Stoffwechsel
Ausgabe04/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction: BIL is a novel, PEGylated basal insulin lispro with large hydrodynamic size. It has a prolonged duration of action. LY2605541 pharmacokinetics (PK) were compared in subjects with varying degrees of hepatic impairment (HI) and healthy subjects. Methods: In this parallel-group, open-label study, 35 subjects received a single 0.33U/kg subcutaneous dose of BIL. Serum was obtained for up to 9 days postdose…
Zitieren
Zitierempfehlung
SL Choi, C Loghin, P Garhyan, MP Knadler, E Lam, V Sinha, N Porksen, H Linnebjerg (2015) A single-dose pharmacokinetic study of basal insulin peglispro (BIL) in subjects with hepatic impairment. Diabetologie und Stoffwechsel (04). https://doi.org/10.1055/s-0035-1549750
Mit CareLit weiterarbeiten